INHIBRX BIOSCIENCES, INC. (INBX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $263.30M; Retained Earnings (Accumulated Deficit)USD $-316.28M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $258.59M; Retained Earnings (Accumulated Deficit)USD $-279.63M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $254.18M; Retained Earnings (Accumulated Deficit)USD $-246.19M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $250.18M; Retained Earnings (Accumulated Deficit)USD $-213.35M.
INHIBRX BIOSCIENCES, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $1.00K | $263.30M | $-316.28M | $-52.98M | 3 month · $3.10M | (m) |
| 2026-03-31 | $0.00 | $1.00K | $258.59M | $-279.63M | $-21.04M | 3 month · $2.65M | 3 month · $1.29M |
| 2025-12-31 | $0.00 | $1.00K | $254.18M | $-246.19M | $7.99M | 12 month · $11.14M | 12 month · $1.72M |
| 2025-09-30 | $0.00 | $1.00K | $250.18M | $-213.35M | $36.83M | 3 month · $3.17M | (m) |
| 2025-06-30 | $0.00 | $1.00K | $246.66M | $-178.10M | $68.56M | 3 month · $2.77M | (m) |
| 2025-03-31 | $0.00 | $1.00K | $243.88M | $-149.44M | $94.44M | 3 month · $2.45M | 3 month · $1.72M |
| 2024-12-31 | $0.00 | $1.00K | $239.72M | $-106.13M | $133.58M | 12 month · $58.52M | (m) |
| 2024-09-30 | $0.00 | $1.00K | $236.73M | $-58.27M | $178.47M | 3 month · $2.96M | (m) |
| 2024-06-30 | $0.00 | $1.00K | $233.77M | $-14.40M | $219.37M | 3 month · $46.17M | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | $11.57M | 3 month · $6.40M | (m) |
| 2023-12-31 | $0.00 | $5.00K | $657.23M | $-613.73M | $43.50M | 12 month · $24.85M | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | $129.59M | 3 month · $6.53M | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | $-24.81M | 3 month · $6.25M | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | $15.13M | 3 month · $5.64M | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | $58.06M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |